IHP Therapeutics Inc.

IHP Therapeutics Inc. is a for-profit corporate entity that provides novel drug and therapeutic development services to federal agencies through grant funding. IHP Therapeutics Inc. specializes in glycan-based therapeutics, leveraging the unique properties of glycans to develop treatments for complex diseases.

Through multiple grant awards from agencies like the National Institutes of Health (NIH) and Department of Defense, IHP Therapeutics Inc. has conducted research on glycan-based therapies for conditions such as sickle cell disease, acute respiratory distress syndrome (ARDS), and vaso-occlusive crises. A major $7.7 million cooperative agreement from NIH's National Institute of Neurological Disorders and Stroke funds the development of a glycan-based selectin and complement inhibitor administered at home for managing sickle cell disease pain crises. Another $3.4 million project grant from NIH's National Heart, Lung, and Blood Institute supports research into an early intervention therapeutic for acute vaso-occlusive crises in sickle cell patients. The company has also received funding from the U.S. Army Medical Command to investigate a novel glycan treatment for ARDS, a critical condition affecting soldiers. Through these federal grants, IHP Therapeutics Inc. advances innovative glycan-based solutions across military and public health applications, with a focus on developing self-administered, disease-modifying therapeutics.